Press Releases - Immatics N.V.
Oct 10, 2024 · Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO …
Immatics Announces $35 Million Equity Investment from Bristol …
Jul 24, 2023 · Tuebingen, Germany and Houston, TX, July 24, 2023 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and …
Moderna and Immatics Announce Strategic Multi-Platform …
Sep 11, 2023 · Collaboration to include evaluation of Immatics’ investigational IMA203 PRAME TCR-T in combination with Moderna’s investigational PRAME mRNA cancer vaccine; …
Immatics Reports Interim Clinical Data from Ongoing Phase 1b …
May 2, 2023 · Houston, Texas and Tuebingen, Germany, May 2, 2023 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the …
Positive Outlook for Immatics Due to Promising Clinical Trial …
6 days ago · Chang covers the Healthcare sector, focusing on stocks such as Immatics, Bicycle Therapeutics, and Xencor. According to TipRanks , Chang has an average return of -4.8% and …
Immatics Announces Multiple Presentations at the 39th Annual …
4 days ago · On October 10, 2024, Immatics provided a data update on IMA203 monotherapy in 28 1 heavily pretreated metastatic melanoma patients from the ongoing Phase 1b dose …
News Archives - Immatics
Oct 10, 2024 · Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming …
Immatics Announces Full Year 2023 Financial Results and …
Mar 21, 2024 · In September 2023, Immatics and Moderna announced a strategic multi-platform collaboration to develop innovative oncology therapeutics; Immatics received $120 million …
Bristol Myers Squibb - Immatics and Bristol Myers Squibb Enter …
Dec 14, 2021 · Bristol Myers Squibb secures global exclusive license to Immatics’ TCR bispecific program IMA401; companies will collaborate on development with Immatics retaining a co …
Immatics Announces $110 Million Underwritten Offering of …
Oct 10, 2022 · Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T …